- Contract Awards
Eli Lilly and Co. (NYSE: LLY) has received a pair of firm-fixed-price contracts worth $2.73 billion combined from the U.S. Army Contracting Command to produce monoclonal antibody drugs for COVID-19. The first contract, valued at $2.52 billion over nine months, covers the supply of coronavirus treatment that combines two neutralizing antibodies, LY-C...









